The studies demonstrate thatwith RevlimidÂ® (an oral cancer drug), all measures of myeloma showed significant improvement in patients. This new class of drugs is a critical advance toward helping address the increase in the number of diagnoses for myeloma. U.S. cancer diagnoses are decreasing, statistics show that the number of myeloma diagnoses is increasing in younger patients(the disease is detected in patients under the age of 40). These trends give us some urgency in having potent treatments to fight this disease.
Revlimid is a drug that can modify the functioning of the immune system. It is the newest therapies. It is an oral drug so it can be taken at home, and because it targets the cancer cells directly along with factors that support their growth, it does not have the difficult side effects.
Patients treated with Revlimid had a median survival of nearly three years (35 months), the longest median survival in this difficult to treat patient group.
Myeloma, is a cancer of the bone marrow that attacks and destroys bone.
An important part of the immune system are normal plasma cells. When plasma cells grow out of control, they can produce a tumor which generally develop in the bone marrow. If there is only one tumor, it is called a plasmacytoma.If myeloma cells can occur in multiple bone marrow sites in your body the disease is called multiple myeloma. several factors which increase the risk of developing multiple myeloma: extensive exposure to radiation, chemical resins, organic solvents, pesticides, and herbicides.
Although once considered a rare disease of the elderly, it is of growing interest and concern.
In Europe and the US, REVLIMIDÂ® is being used to threat myeloma. In the US it is also approved for a pre-leukemia condition called myelodysplastic syndrome (MDS). It is also being tested in other leukemias, lymphomas, and solid tumors.
In Europe and the U.S., Revlimid has been used to threat myeloma, and in the U.S. it is also approved for a pre-leukemia condition called MDS (myelodysplastic syndrome).